What's Happening?
IMMEDIATE Therapeutics, a clinical-stage biotechnology company, has announced significant additions to its Scientific Advisory Board and leadership team to advance its late-stage therapy, IMT-358. This therapy is designed for acute coronary syndromes
and other ischemic emergencies, aiming to enable immediate intervention at the point of care. The company has appointed Norman L. Stockbridge, M.D., Ph.D., former FDA Cardiovascular Division Director, to its Scientific Advisory Board. Additionally, Bradley Newman has been named Global Head of Manufacturing and Supply Chain, and Chia-Wen Lee, Ph.D., has been appointed Global Head of Market Access. IMT-358 is a Phase 3-ready therapy that has received FDA Breakthrough Therapy Designation and is being advanced under a Special Protocol Assessment with the FDA. The therapy is designed to provide rapid deployment in both prehospital and in-hospital settings, with the goal of improving survival and preserving organ function.
Why It's Important?
The development of IMT-358 is crucial as acute coronary syndromes remain a leading cause of mortality and morbidity in the United States. More than 1.5 million patients experience an acute coronary syndrome annually in the U.S., with many eligible for early intervention. Current therapies often begin too late, leading to significant myocardial injury and subsequent complications such as heart failure. IMT-358 aims to address this gap by enabling early intervention, potentially reducing the extent of damage and associated healthcare costs. The therapy's development reflects a strategic alignment with clinical and regulatory requirements, ensuring it can be seamlessly integrated into existing care pathways and reimbursement frameworks.
What's Next?
IMMEDIATE Therapeutics is advancing towards a pivotal Phase 3 trial for IMT-358, which will evaluate clinically meaningful endpoints such as in-hospital cardiac arrest, mortality, and infarct size. The company is also focusing on ensuring manufacturing readiness to meet clinical and regulatory progress, aiming for rapid deployment upon approval. Engagement with payers and health systems is ongoing to facilitate broad adoption of the therapy as clinical data emerges. The leadership team, with extensive experience in regulatory frameworks, manufacturing, and market access, is poised to drive the therapy's successful integration into the healthcare system.
